As an oral dual HER2/EGFR tyrosine kinase inhibitor, lapatinib could provide anti-cancer efficacy in pretreated and trastuzumab-resistant breast cancer patients, and the combination of trastuzumab and lapatinib improved the outcome in the neoadjuvant and metastatic setting [93,94,95]. This evidence concerns the gene ERBB2 and breast carcinoma.